vs
渤健（BIIB）与CSX Corporation（CSX）财务数据对比。点击上方公司名可切换其他公司
CSX Corporation的季度营收约是渤健的1.5倍（$3.5B vs $2.3B），CSX Corporation净利率更高（23.2% vs -2.1%，领先25.3%），CSX Corporation同比增速更快（1.7% vs -7.1%），CSX Corporation自由现金流更多（$793.0M vs $468.0M），过去两年渤健的营收复合增速更高（-0.2% vs -3.0%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
CSX运输是美国一级货运铁路企业，业务覆盖美国东部区域及加拿大安大略省、魁北克省，运营铁路总里程约3.4万公里，隶属于总部位于佛罗里达州杰克逊维尔市的财富500强企业CSX Corporation，是其旗下核心子公司。
BIIB vs CSX — 直观对比
营收规模更大
CSX
是对方的1.5倍
$2.3B
营收增速更快
CSX
高出8.9%
-7.1%
净利率更高
CSX
高出25.3%
-2.1%
自由现金流更多
CSX
多$325.0M
$468.0M
两年增速更快
BIIB
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $3.5B |
| 净利润 | $-48.9M | $807.0M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 29.9% |
| 净利率 | -2.1% | 23.2% |
| 营收同比 | -7.1% | 1.7% |
| 净利润同比 | -118.3% | 401.2% |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBCSX
| Q1 26 | — | $3.5B | ||
| Q4 25 | $2.3B | $3.5B | ||
| Q3 25 | $2.5B | $3.6B | ||
| Q2 25 | $2.6B | $3.6B | ||
| Q1 25 | $2.4B | $3.4B | ||
| Q4 24 | $2.5B | $3.5B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.5B | $3.7B |
净利润BIIBCSX
| Q1 26 | — | $807.0M | ||
| Q4 25 | $-48.9M | $720.0M | ||
| Q3 25 | $466.5M | $694.0M | ||
| Q2 25 | $634.8M | $829.0M | ||
| Q1 25 | $240.5M | $646.0M | ||
| Q4 24 | $266.7M | $720.0M | ||
| Q3 24 | $388.5M | $894.0M | ||
| Q2 24 | $583.6M | $963.0M |
毛利率BIIBCSX
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBCSX
| Q1 26 | — | 29.9% | ||
| Q4 25 | -2.5% | 31.6% | ||
| Q3 25 | 22.0% | 30.3% | ||
| Q2 25 | 28.1% | 35.9% | ||
| Q1 25 | 12.8% | 30.4% | ||
| Q4 24 | 11.9% | 30.8% | ||
| Q3 24 | 18.3% | 37.4% | ||
| Q2 24 | 28.3% | 39.1% |
净利率BIIBCSX
| Q1 26 | — | 23.2% | ||
| Q4 25 | -2.1% | 20.5% | ||
| Q3 25 | 18.4% | 19.3% | ||
| Q2 25 | 24.0% | 23.2% | ||
| Q1 25 | 9.9% | 18.9% | ||
| Q4 24 | 10.9% | 20.3% | ||
| Q3 24 | 15.8% | 24.7% | ||
| Q2 24 | 23.7% | 26.0% |
每股收益（稀释后）BIIBCSX
| Q1 26 | — | — | ||
| Q4 25 | $-0.35 | $0.39 | ||
| Q3 25 | $3.17 | $0.37 | ||
| Q2 25 | $4.33 | $0.44 | ||
| Q1 25 | $1.64 | $0.34 | ||
| Q4 24 | $1.82 | $0.38 | ||
| Q3 24 | $2.66 | $0.46 | ||
| Q2 24 | $4.00 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.1B |
| 总债务越低越好 | $6.3B | $18.9B |
| 股东权益账面价值 | $18.3B | $13.6B |
| 总资产 | $29.4B | $44.2B |
| 负债/权益比越低杠杆越低 | 0.34× | 1.39× |
8季度趋势，按日历期对齐
现金及短期投资BIIBCSX
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $72.0M | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $4.0M |
总债务BIIBCSX
| Q1 26 | — | $18.9B | ||
| Q4 25 | $6.3B | $18.2B | ||
| Q3 25 | $6.3B | $18.6B | ||
| Q2 25 | $6.3B | $18.6B | ||
| Q1 25 | $4.5B | $18.5B | ||
| Q4 24 | $6.3B | $17.9B | ||
| Q3 24 | $4.5B | $18.5B | ||
| Q2 24 | $6.3B | $18.0B |
股东权益BIIBCSX
| Q1 26 | — | $13.6B | ||
| Q4 25 | $18.3B | $13.2B | ||
| Q3 25 | $18.2B | $12.8B | ||
| Q2 25 | $17.6B | $12.4B | ||
| Q1 25 | $17.0B | $12.2B | ||
| Q4 24 | $16.7B | $12.5B | ||
| Q3 24 | $16.4B | $12.9B | ||
| Q2 24 | $15.9B | $12.6B |
总资产BIIBCSX
| Q1 26 | — | $44.2B | ||
| Q4 25 | $29.4B | $43.7B | ||
| Q3 25 | $29.2B | $43.3B | ||
| Q2 25 | $28.3B | $42.9B | ||
| Q1 25 | $28.0B | $43.2B | ||
| Q4 24 | $28.0B | $42.8B | ||
| Q3 24 | $28.3B | $43.1B | ||
| Q2 24 | $26.8B | $42.4B |
负债/权益比BIIBCSX
| Q1 26 | — | 1.39× | ||
| Q4 25 | 0.34× | 1.38× | ||
| Q3 25 | 0.35× | 1.45× | ||
| Q2 25 | 0.36× | 1.50× | ||
| Q1 25 | 0.27× | 1.52× | ||
| Q4 24 | 0.38× | 1.43× | ||
| Q3 24 | 0.28× | 1.43× | ||
| Q2 24 | 0.40× | 1.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $793.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 22.8% |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | 1.58× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $2.0B |
8季度趋势，按日历期对齐
经营现金流BIIBCSX
| Q1 26 | — | $1.3B | ||
| Q4 25 | $511.9M | $1.4B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $160.9M | $635.0M | ||
| Q1 25 | $259.3M | $1.3B | ||
| Q4 24 | $760.9M | $1.4B | ||
| Q3 24 | $935.6M | $1.7B | ||
| Q2 24 | $625.8M | $1.1B |
自由现金流BIIBCSX
| Q1 26 | — | $793.0M | ||
| Q4 25 | $468.0M | $709.0M | ||
| Q3 25 | $1.2B | $607.0M | ||
| Q2 25 | $134.3M | $-141.0M | ||
| Q1 25 | $222.2M | $536.0M | ||
| Q4 24 | $721.6M | $550.0M | ||
| Q3 24 | $900.6M | $1.1B | ||
| Q2 24 | $592.3M | $547.0M |
自由现金流率BIIBCSX
| Q1 26 | — | 22.8% | ||
| Q4 25 | 20.5% | 20.2% | ||
| Q3 25 | 48.4% | 16.9% | ||
| Q2 25 | 5.1% | -3.9% | ||
| Q1 25 | 9.1% | 15.7% | ||
| Q4 24 | 29.4% | 15.5% | ||
| Q3 24 | 36.5% | 29.3% | ||
| Q2 24 | 24.0% | 14.8% |
资本支出强度BIIBCSX
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 19.3% | ||
| Q3 25 | 1.8% | 20.4% | ||
| Q2 25 | 1.0% | 21.7% | ||
| Q1 25 | 1.5% | 21.0% | ||
| Q4 24 | 1.6% | 23.7% | ||
| Q3 24 | 1.4% | 17.3% | ||
| Q2 24 | 1.4% | 14.6% |
现金转化率BIIBCSX
| Q1 26 | — | 1.58× | ||
| Q4 25 | — | 1.93× | ||
| Q3 25 | 2.73× | 1.93× | ||
| Q2 25 | 0.25× | 0.77× | ||
| Q1 25 | 1.08× | 1.94× | ||
| Q4 24 | 2.85× | 1.93× | ||
| Q3 24 | 2.41× | 1.89× | ||
| Q2 24 | 1.07× | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
CSX
暂无分部数据
